Trial · NCT03201458
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Arm A (Atezolizumab) | Progression free at 1 Year after Randomization | 0 | Participants | |
| Progression Free Survival (PFS) | Arm B (Atezolizumab, Cobimetinib) | Progression free at 1 Year after Randomization | 3 | Participants | |
| Progression Free Survival (PFS) | Arm A (Atezolizumab) | Progressed or Off Treatment by 1 Year after Randomization | 39 | Participants | |
| Progression Free Survival (PFS) | Arm B (Atezolizumab, Cobimetinib) | Progressed or Off Treatment by 1 Year after Randomization | 35 | Participants | |
| Number of Participants With Adverse Events | Arm A (Atezolizumab) | Grade 3 or higher adverse event considered at least possibly related to the study drug(s) | 15 | Participants | |
| Number of Participants With Adverse Events | Arm B (Atezolizumab, Cobimetinib) | Grade 3 or higher adverse event considered at least possibly related to the study drug(s) | 17 | Participants | |
| Number of Participants With Adverse Events | Arm A (Atezolizumab) | No grade 3 or higher adverse events considered at least possibly related to the study drug(s) | 24 | Participants | |
| Number of Participants With Adverse Events | Arm B (Atezolizumab, Cobimetinib) | No grade 3 or higher adverse events considered at least possibly related to the study drug(s) | 21 | Participants | |
| Objective Response Rate | Arm A (Atezolizumab) | Complete Response | 0 | Participants | |
| Objective Response Rate | Arm B (Atezolizumab, Cobimetinib) | Complete Response | 0 | Participants | |
| Objective Response Rate | Arm A (Atezolizumab) | Partial Response | 1 | Participants | |
| Objective Response Rate | Arm B (Atezolizumab, Cobimetinib) | Partial Response | 1 | Participants | |
| Objective Response Rate | Arm A (Atezolizumab) | Stable Disease | 10 | Participants | |
| Objective Response Rate | Arm B (Atezolizumab, Cobimetinib) | Stable Disease | 13 | Participants | |
| Objective Response Rate | Arm A (Atezolizumab) | Clinical or Radiographic Progression | 25 | Participants | |
| Objective Response Rate | Arm B (Atezolizumab, Cobimetinib) | Clinical or Radiographic Progression | 16 | Participants | |
| Overall Survival | Arm A (Atezolizumab) | Alive at 1 year | 9 | Participants | |
| Overall Survival | Arm B (Atezolizumab, Cobimetinib) | Alive at 1 year | 9 | Participants | |
| Overall Survival | Arm A (Atezolizumab) | Deceased or Lost to Follow Up at 1 year | 30 | Participants | |
| Overall Survival | Arm B (Atezolizumab, Cobimetinib) | Deceased or Lost to Follow Up at 1 year | 29 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03201458/results